(PubMed) Eng WK, Giraud D, Schlegel VL, Wang D, Lee BH, Zempleni J
This medication doesnt just suppress appetiteit rewires the conversation between your gut and your brain
Ipamorelin is also known as NNC 26-0161 (research designation), Growth Hormone Secretagogue, GHS-R1a Agonist, and Selective GH Secretagogue
Adverse Reactions Reported during Post-Marketing Experience * Body System represented from COSTART medical dictionary
9 The consensus statement from the American Association of Clinical Endocrinologists supports the use of GLP-1 RAs as first-line therapy in managing hyperglycaemia in T2D patients with established (or at high risk of) atherosclerotic CVD, as well as in those with chronic kidney disease or a history of stroke or transient ischaemic attack, while recommending the administration of sodiumglucose cotransporter 2 inhibitors to HF patients